Helena Hognert
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Helena Hognert has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Kristina Gemzell-Danielsson
Department of Women's and Children's Health Karolinska Institutet Stockholm Sweden
7 shared publications - Ian Milsom
Gothenburg Continence Research Centre Institute of Clinical Sciences, Sahlgrenska Academy at Gothenburg University Gothenburg Sweden
4 shared publications - Ingela Lindh
Department of Obstetrics and Gynecology, Sahlgrenska Academy at Gothenburg University, Sahlgrenska University Hospital, Gothenburg, Sweden
4 shared publications - Oskari Heikinheimo
Department of Obstetrics and Gynecology University of Helsinki and Helsinki University Hospital Helsinki Finland
4 shared publications - Finn Egil Skjeldestad
Department of Community Medicine, UiT The Arctic University of Norway, 9037 Tromsø, Norway
2 shared publications - Helena Kopp Kallner
Department of Clinical Sciences at Danderyd Hospital, Karolinska Institutet
2 shared publications
Latest Publications
- Open Access
- 11 August 2025
- Published by BMJ in BMJ Sexual & Reproductive Health
- Vol. 52 (1) , 19-25
Pain management for medical abortion beyond 12 weeks of gestation: a cross-sectional study in Sweden
Background: Medical abortion beyond 12 weeks’ gestation increases experienced pain. The effectiveness of pain management protocols remains to be evaluated. Methods: This was a secondary analysis of a randomised controlled trial, conducted in six Swedish hospitals from 2019 to 2022, investigating home administration of the first misoprostol dose. Paracetamol 1000 mg and a non-steroidal anti-inflammatory drug (NSAID) were provided with the first misoprostol dose and subsequent breakthrough pain medication as required. We recruited persons >18 years of age, with a viable singleton pregnancy between 12 weeks+1 day and 21 weeks+6 days of gestation. We collected data on patient-reported pain using a visual analogue scale (VAS, 0–100 mm) at fetal expulsion and maximum pain assessed retrospectively prior to discharge. We collected data on the use of breakthrough pain medication, satisfaction scores with pain relief, and VAS scores before/after administration of breakthrough analgesia. Results: We included 425 individuals. The participants reported a mean VAS of 39.1 (SD 34.4) at expulsion and 65.4 (SD 28.6) as maximum pain (assessed after abortion before discharge) and 352/425 (82.8%) received breakthrough pain medication, with 266/425 (62.6%) receiving an oral opioid, 163/425 (38.4%) a paracervical block (PCB) and 86/425 (20.2%) a parenteral opioid. A total of 357/392 (91.1%) participants were satisfied with the pain relief. Administration of a PCB alone or following an opioid resulted in the largest decrease in VAS. Conclusions: Many participants reported high VAS scores but most of them were satisfied with their analgesic treatment. A PCB was associated with the highest effectiveness in alleviating pain.
- 11 August 2025
- Published by BMJ in BMJ Sexual & Reproductive Health
- Vol. 52 (1) , 19-25
Open AccessPain management for medical abortion beyond 12 weeks of gestation: a cross-sectional study in Sweden
Background: Medical abortion beyond 12 weeks’ gestation increases experienced pain. The effectiveness of pain management protocols remains to be evaluated. Methods: This was a secondary analysis of a randomised controlled trial, conducted in six Swedish hospitals from 2019 to 2022, investigating home administration of the first misoprostol dose. Paracetamol 1000 mg and a non-steroidal anti-inflammatory drug (NSAID) were provided with the first misoprostol dose and subsequent breakthrough pain medication as required. We recruited persons >18 years of age, with a viable singleton pregnancy between 12 weeks+1 day and 21 weeks+6 days of gestation. We collected data on patient-reported pain using a visual analogue scale (VAS, 0–100 mm) at fetal expulsion and maximum pain assessed retrospectively prior to discharge. We collected data on the use of breakthrough pain medication, satisfaction scores with pain relief, and VAS scores before/after administration of breakthrough analgesia. Results: We included 425 individuals. The participants reported a mean VAS of 39.1 (SD 34.4) at expulsion and 65.4 (SD 28.6) as maximum pain (assessed after abortion before discharge) and 352/425 (82.8%) received breakthrough pain medication, with 266/425 (62.6%) receiving an oral opioid, 163/425 (38.4%) a paracervical block (PCB) and 86/425 (20.2%) a parenteral opioid. A total of 357/392 (91.1%) participants were satisfied with the pain relief. Administration of a PCB alone or following an opioid resulted in the largest decrease in VAS. Conclusions: Many participants reported high VAS scores but most of them were satisfied with their analgesic treatment. A PCB was associated with the highest effectiveness in alleviating pain.
- Open Access
- 2 July 2025
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 104 (9) , 1665-1671
Differences in pain, bleeding, and satisfaction during medical abortion at very early gestations
Introduction: Little is known regarding the impact of gestation on pain, bleeding duration, and satisfaction in early medical abortion (termination of pregnancy). This study aimed to determine if pain experience, bleeding duration, and overall satisfaction with medical abortion differed across four ultrasound‐defined categories of early pregnancy.Material and Methods: This is a secondary analysis of the multicenter VEMA‐trial, a randomized clinical trial on the efficacy and safety of very early medical abortion before confirming pregnancy location (the VEMA‐trial, EudraCT 2018‐003675‐35, ClinicalTrials.gov NCT03989869). The present study included participants with normally developing pregnancies and known abortion outcomes, including complete abortion, incomplete abortion, and ongoing pregnancy, that is, pregnancy still progressing after medical abortion. Participants were grouped by ultrasound findings at the time of abortion into pregnancy of unknown location, early, normally sited pregnancy (empty sac), and normally sited pregnancy with visible yolk sac or visible embryo. Pain experience was measured on the 0–10 numeric rating scale (higher values for more pain), duration of bleeding in days, and satisfaction on a 0–6 scale (higher values indicating greater satisfaction).Results: Altogether 1253 participants were included: 18% (224 participants) with pregnancy of unknown location, 38% (476) with early, normally sited pregnancy, 24% (301) with visible yolk sac, and 20% (252) with visible embryo. Pain scores were lowest in the pregnancy of unknown location group (mean 5.2 ± SD 2.3) and highest in the pregnancy with visible embryo group (6.2 ± 2.4). Bleeding duration was shortest for pregnancies of unknown location (4.9 ± 3.2) and longest for those with visible embryo (7.5 ± 5.3). Mean satisfaction was over 5 in all groups, highest in early, normally sited pregnancies (5.7 ± 0.7). In regression analyses, both pain scores and bleeding duration increased with advancing ultrasound findings. The pregnancy of unknown location group reported the least pain (1.02 points lower, 95% Confidence Interval [CI] −1.46 to −0.57) and the shortest bleeding duration (34% shorter, incidence rate ratio 0.66, 95% CI 0.61 to 0.71) compared to pregnancies with visible embryo.Conclusions: More advanced ultrasound findings are associated with higher pain scores and longer bleeding duration in very early medical abortion, whereas satisfaction is high across ultrasound‐defined categories.
- 2 July 2025
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 104 (9) , 1665-1671
Open AccessDifferences in pain, bleeding, and satisfaction during medical abortion at very early gestations
Introduction: Little is known regarding the impact of gestation on pain, bleeding duration, and satisfaction in early medical abortion (termination of pregnancy). This study aimed to determine if pain experience, bleeding duration, and overall satisfaction with medical abortion differed across four ultrasound‐defined categories of early pregnancy.Material and Methods: This is a secondary analysis of the multicenter VEMA‐trial, a randomized clinical trial on the efficacy and safety of very early medical abortion before confirming pregnancy location (the VEMA‐trial, EudraCT 2018‐003675‐35, ClinicalTrials.gov NCT03989869). The present study included participants with normally developing pregnancies and known abortion outcomes, including complete abortion, incomplete abortion, and ongoing pregnancy, that is, pregnancy still progressing after medical abortion. Participants were grouped by ultrasound findings at the time of abortion into pregnancy of unknown location, early, normally sited pregnancy (empty sac), and normally sited pregnancy with visible yolk sac or visible embryo. Pain experience was measured on the 0–10 numeric rating scale (higher values for more pain), duration of bleeding in days, and satisfaction on a 0–6 scale (higher values indicating greater satisfaction).Results: Altogether 1253 participants were included: 18% (224 participants) with pregnancy of unknown location, 38% (476) with early, normally sited pregnancy, 24% (301) with visible yolk sac, and 20% (252) with visible embryo. Pain scores were lowest in the pregnancy of unknown location group (mean 5.2 ± SD 2.3) and highest in the pregnancy with visible embryo group (6.2 ± 2.4). Bleeding duration was shortest for pregnancies of unknown location (4.9 ± 3.2) and longest for those with visible embryo (7.5 ± 5.3). Mean satisfaction was over 5 in all groups, highest in early, normally sited pregnancies (5.7 ± 0.7). In regression analyses, both pain scores and bleeding duration increased with advancing ultrasound findings. The pregnancy of unknown location group reported the least pain (1.02 points lower, 95% Confidence Interval [CI] −1.46 to −0.57) and the shortest bleeding duration (34% shorter, incidence rate ratio 0.66, 95% CI 0.61 to 0.71) compared to pregnancies with visible embryo.Conclusions: More advanced ultrasound findings are associated with higher pain scores and longer bleeding duration in very early medical abortion, whereas satisfaction is high across ultrasound‐defined categories.
- 29 August 2024
- Published by Elsevier in The Lancet
- Vol. 404 (10455) , 864-873
First dose of misoprostol administration at home or in hospital for medical abortion between 12–22 gestational weeks in Sweden (PRIMA): a multicentre, open-label, randomised controlled trial
- 29 August 2024
- Published by Elsevier in The Lancet
- Vol. 404 (10455) , 864-873
First dose of misoprostol administration at home or in hospital for medical abortion between 12–22 gestational weeks in Sweden (PRIMA): a multicentre, open-label, randomised controlled trial
- 21 January 2022
- Published by Taylor & Francis in The European Journal of Contraception & Reproductive Health Care
- Vol. 27 (3) , 240-246
Detection of ectopic pregnancy and serum beta hCG levels in women undergoing very early medical abortion: a retrospective cohort study
To evaluate the outcome of the very early medical abortion (VEMA) protocol and whether it could increase early diagnosis and treatment of an asymptomatic ectopic pregnancy (EP). To investigate seru...
- 21 January 2022
- Published by Taylor & Francis in The European Journal of Contraception & Reproductive Health Care
- Vol. 27 (3) , 240-246
Detection of ectopic pregnancy and serum beta hCG levels in women undergoing very early medical abortion: a retrospective cohort study
To evaluate the outcome of the very early medical abortion (VEMA) protocol and whether it could increase early diagnosis and treatment of an asymptomatic ectopic pregnancy (EP). To investigate seru...
- Open Access
- 5 January 2022
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 101 (2) , 248-255
Reproductive changes among women in their 40s: A cross‐sectional study
Introduction: The aim was to describe and compare changes in the reproductive pattern of women in their 40s observed over a decade in Scandinavia.Material and Methods: Cross‐sectional study using the total population of women aged 40–49 years between 2008–2018 in Denmark, Norway and Sweden (on average n = 1.5 million). Aggregated data concerning birth and induced abortion rate were collected and analyzed from national health registers. National data on redeemed prescriptions of hormonal contraceptives in the three countries were collected from prescription registers. Births after spontaneous and assisted conceptions were identified by using cross‐linked data on deliveries from the Medical Birth Registers and National Registers of Assisted Reproduction in the three countries.Results: Use of hormonal contraception increased among women aged 40–44 years in Denmark from 24% to 31%, in Sweden from 27% to 30%, and in Norway from 22% to 24%. The levonorgestrel‐releasing intrauterine device was the most frequently used method in all countries. Birth rates among women 40–44 years increased continuously from 9.5 to 12/1000 women in Denmark and from 11.7 to 14.3/1000 in Sweden, but remained stable in Norway at ~11/1000 women. There was a doubling of assisted conceptions in Denmark from 0.71 to 1.71/1000 women, Sweden from 0.43 to 0.81/1000 and Norway from 0.25 to 0.53/1000 women 40–49 years of age. Sweden had the highest induced abortion rate (7.7 to 8.1/1000 women) in women aged 40–49 years during the study period.Conclusions: From 2008 to 2018, birth rates continuously increased among women aged 40–49 years in Denmark and Sweden and births resulting from assisted reproductive technology doubled in all three countries.
- 5 January 2022
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 101 (2) , 248-255
Open AccessReproductive changes among women in their 40s: A cross‐sectional study
Introduction: The aim was to describe and compare changes in the reproductive pattern of women in their 40s observed over a decade in Scandinavia.Material and Methods: Cross‐sectional study using the total population of women aged 40–49 years between 2008–2018 in Denmark, Norway and Sweden (on average n = 1.5 million). Aggregated data concerning birth and induced abortion rate were collected and analyzed from national health registers. National data on redeemed prescriptions of hormonal contraceptives in the three countries were collected from prescription registers. Births after spontaneous and assisted conceptions were identified by using cross‐linked data on deliveries from the Medical Birth Registers and National Registers of Assisted Reproduction in the three countries.Results: Use of hormonal contraception increased among women aged 40–44 years in Denmark from 24% to 31%, in Sweden from 27% to 30%, and in Norway from 22% to 24%. The levonorgestrel‐releasing intrauterine device was the most frequently used method in all countries. Birth rates among women 40–44 years increased continuously from 9.5 to 12/1000 women in Denmark and from 11.7 to 14.3/1000 in Sweden, but remained stable in Norway at ~11/1000 women. There was a doubling of assisted conceptions in Denmark from 0.71 to 1.71/1000 women, Sweden from 0.43 to 0.81/1000 and Norway from 0.25 to 0.53/1000 women 40–49 years of age. Sweden had the highest induced abortion rate (7.7 to 8.1/1000 women) in women aged 40–49 years during the study period.Conclusions: From 2008 to 2018, birth rates continuously increased among women aged 40–49 years in Denmark and Sweden and births resulting from assisted reproductive technology doubled in all three countries.
- 30 October 2017
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 96 (12) , 1414-1422
High birth rates despite easy access to contraception and abortion: a cross‐sectional study
Introduction: The aim of this study was to describe and compare contraceptive use, fertility, birth, and abortion rates in the Nordic countries.Material and methods: National data on births, abortions, fertility rate (1975–2013), redeemed prescriptions of hormonal contraceptives and sales figures of copper intrauterine devices (2008–2013) among women 15–49 years of age in the Nordic countries were collected and analyzed.Results: Use of hormonal contraceptives and copper intrauterine devices varied between 31 and 44%. The highest use was in Denmark (39–44%) and Sweden (40–42%). Combined hormonal contraception followed by the levonorgestrel‐releasing intrauterine system were the most common methods. During 1975–2013 abortion rates decreased in Denmark (from 27/1000 women to 15/1000 women aged 15–44/1000 women) and Finland (from 20 to 10/1000 women), remained stable in Norway (≈16) and Sweden (≈20) and increased in Iceland (from 6 to 15/1000 women). Birth rates remained stable around 60/1000 women aged 15–44 in all countries except for Iceland where the birth rate decreased from 95 to 65/1000 women. Abortion rates were highest in the age group 20–24 years. In the same age group, Sweden had a lower contraceptive use (51%) compared with Denmark (59%) and Norway (56%) and a higher abortion rate 33/1000 compared with Denmark (25/1000) and Norway (27/1000).Conclusions: In contrast to the declining average fertility and birth rates in Europe, rates in the Nordic countries remain high and stable despite high contraceptive use and liberal access to abortion on women's request.
- 30 October 2017
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 96 (12) , 1414-1422
High birth rates despite easy access to contraception and abortion: a cross‐sectional study
Introduction: The aim of this study was to describe and compare contraceptive use, fertility, birth, and abortion rates in the Nordic countries.Material and methods: National data on births, abortions, fertility rate (1975–2013), redeemed prescriptions of hormonal contraceptives and sales figures of copper intrauterine devices (2008–2013) among women 15–49 years of age in the Nordic countries were collected and analyzed.Results: Use of hormonal contraceptives and copper intrauterine devices varied between 31 and 44%. The highest use was in Denmark (39–44%) and Sweden (40–42%). Combined hormonal contraception followed by the levonorgestrel‐releasing intrauterine system were the most common methods. During 1975–2013 abortion rates decreased in Denmark (from 27/1000 women to 15/1000 women aged 15–44/1000 women) and Finland (from 20 to 10/1000 women), remained stable in Norway (≈16) and Sweden (≈20) and increased in Iceland (from 6 to 15/1000 women). Birth rates remained stable around 60/1000 women aged 15–44 in all countries except for Iceland where the birth rate decreased from 95 to 65/1000 women. Abortion rates were highest in the age group 20–24 years. In the same age group, Sweden had a lower contraceptive use (51%) compared with Denmark (59%) and Norway (56%) and a higher abortion rate 33/1000 compared with Denmark (25/1000) and Norway (27/1000).Conclusions: In contrast to the declining average fertility and birth rates in Europe, rates in the Nordic countries remain high and stable despite high contraceptive use and liberal access to abortion on women's request.
- 29 December 2016
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 96 (1) , 19-28
Contraceptive use in the Nordic countries
Introduction: The aim was to compare contraceptive use in the Nordic countries and to assess compliance with recommendations from the European Medicines Agency regarding the use of combined oral contraception containing low‐dose estrogen and levonorgestrel, norethisterone or norgestimate.Material and methods: Data on hormonal contraceptive prescriptions and sales figures for copper intrauterine devices were obtained from national databases and manufacturers in Denmark, Finland, Iceland, Norway and Sweden in 2010–2013.Results: Contraceptive use was highest in Denmark (42%) and Sweden (41%), followed by Finland (40%). Combined oral contraception was the most used method in all countries, with the highest use in Denmark (26%). The second most used method was the levonorgestrel‐releasing intrauterine system, with the highest use in Finland (15%) and ≈10% in the other countries. Copper intrauterine devices (7%) and the progestin‐only pill (7%) were most often used in Sweden. Combined oral contraception use decreased with increasing age and levonorgestrel‐releasing intrauterine system and progestin‐only pills use increased. The use of long‐acting reversible methods of contraception (=levonorgestrel‐releasing intrauterine system, copper intrauterine devices, and implants) increased with time and was highest in Sweden (20%) and Finland (18%). The highest use of European Medicines Agency recommended combined oral contraception was in Denmark, increasing from 13 to 50% between 2010 and 2013. In Finland, recommended combined oral contraception remained below 1%.Conclusions: Contraceptive use was highest in Denmark and Sweden, levonorgestrel‐releasing intrauterine system use was highest in Finland and all long‐acting methods were most common in Sweden. The use of combined oral contraception recommended by the European Medicines Agency was highest in Denmark.
- 29 December 2016
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 96 (1) , 19-28
Contraceptive use in the Nordic countries
Introduction: The aim was to compare contraceptive use in the Nordic countries and to assess compliance with recommendations from the European Medicines Agency regarding the use of combined oral contraception containing low‐dose estrogen and levonorgestrel, norethisterone or norgestimate.Material and methods: Data on hormonal contraceptive prescriptions and sales figures for copper intrauterine devices were obtained from national databases and manufacturers in Denmark, Finland, Iceland, Norway and Sweden in 2010–2013.Results: Contraceptive use was highest in Denmark (42%) and Sweden (41%), followed by Finland (40%). Combined oral contraception was the most used method in all countries, with the highest use in Denmark (26%). The second most used method was the levonorgestrel‐releasing intrauterine system, with the highest use in Finland (15%) and ≈10% in the other countries. Copper intrauterine devices (7%) and the progestin‐only pill (7%) were most often used in Sweden. Combined oral contraception use decreased with increasing age and levonorgestrel‐releasing intrauterine system and progestin‐only pills use increased. The use of long‐acting reversible methods of contraception (=levonorgestrel‐releasing intrauterine system, copper intrauterine devices, and implants) increased with time and was highest in Sweden (20%) and Finland (18%). The highest use of European Medicines Agency recommended combined oral contraception was in Denmark, increasing from 13 to 50% between 2010 and 2013. In Finland, recommended combined oral contraception remained below 1%.Conclusions: Contraceptive use was highest in Denmark and Sweden, levonorgestrel‐releasing intrauterine system use was highest in Finland and all long‐acting methods were most common in Sweden. The use of combined oral contraception recommended by the European Medicines Agency was highest in Denmark.
- 19 October 2016
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 95 (11) , 1264-1272
The changing pattern of contraceptive use and pregnancies in four generations of young women
Introduction: The aim of this study was to describe contraceptive use and pregnancies and their relationship to socio‐economic status (SES) in four generations of young Swedish women.Material and methods: Questionnaires regarding contraceptive use and pregnancies were sent to random samples of 19‐year‐old women in 1981, 1991, 2001 and 2011 (n = 4732).Results: Current contraceptive use was higher in 2001 (78%) (p < 0.01) and 2011 (69%) (p < 0.05) compared with 1981 (60%) and 1991 (62%). Combined hormonal contraception (CHC) was the most common form of contraception throughout (p < 0.0001). The use of long‐acting reversible contraception (LARC = implants, intrauterine contraception) and progestogen‐only pills increased over time (p < 0.01). Mental side effects as a reason for CHC cessation increased over time and was the most common reason for cessation of CHC in 2011 (p < 0.001). Contraceptive use was lower in women from low SES areas (p < 0.05) in 2011. The percentage of young women who had been pregnant at ≤19 years of age was lower (p < 0.05) in the assessment from 2001 (7%) than in that in 1991 (13%) and 2011 (12%). The proportion of teenage mothers decreased from 4.4% (1981) to 1.6% (2011) (p < 0.01). More women had been pregnant at ≤19 years of age in low SES areas than in middle and high SES areas (p < 0.05).Conclusions: The lowest pregnancy rate was in the cohort with the highest contraceptive use. Term pregnancies declined over time. A greater number of pregnancies in low SES areas and a change towards lower contraceptive use in low SES areas was recorded in 2011.
- 19 October 2016
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 95 (11) , 1264-1272
The changing pattern of contraceptive use and pregnancies in four generations of young women
Introduction: The aim of this study was to describe contraceptive use and pregnancies and their relationship to socio‐economic status (SES) in four generations of young Swedish women.Material and methods: Questionnaires regarding contraceptive use and pregnancies were sent to random samples of 19‐year‐old women in 1981, 1991, 2001 and 2011 (n = 4732).Results: Current contraceptive use was higher in 2001 (78%) (p < 0.01) and 2011 (69%) (p < 0.05) compared with 1981 (60%) and 1991 (62%). Combined hormonal contraception (CHC) was the most common form of contraception throughout (p < 0.0001). The use of long‐acting reversible contraception (LARC = implants, intrauterine contraception) and progestogen‐only pills increased over time (p < 0.01). Mental side effects as a reason for CHC cessation increased over time and was the most common reason for cessation of CHC in 2011 (p < 0.001). Contraceptive use was lower in women from low SES areas (p < 0.05) in 2011. The percentage of young women who had been pregnant at ≤19 years of age was lower (p < 0.05) in the assessment from 2001 (7%) than in that in 1991 (13%) and 2011 (12%). The proportion of teenage mothers decreased from 4.4% (1981) to 1.6% (2011) (p < 0.01). More women had been pregnant at ≤19 years of age in low SES areas than in middle and high SES areas (p < 0.05).Conclusions: The lowest pregnancy rate was in the cohort with the highest contraceptive use. Term pregnancies declined over time. A greater number of pregnancies in low SES areas and a change towards lower contraceptive use in low SES areas was recorded in 2011.